Provided by Tiger Trade Technology Pte. Ltd.

Fennec Pharmaceuticals Inc.

7.84
+0.18002.35%
Post-market: 7.840.00000.00%16:10 EST
Volume:91.32K
Turnover:711.76K
Market Cap:267.76M
PE:-29.94
High:7.95
Open:7.75
Low:7.55
Close:7.66
52wk High:9.92
52wk Low:4.68
Shares:34.15M
Float Shares:22.75M
Volume Ratio:0.74
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.2619
EPS(LYR):-0.0200
ROE:-1005.59%
ROA:-5.39%
PB:-59.61
PE(LYR):-392.00

Loading ...

Fennec Pharmaceuticals Director Rosty Raykov Reports Disposal of Common Shares

Reuters
·
Feb 03

Piper Sandler Initiates Fennec Pharmaceuticals at Overweight

MT Newswires Live
·
Jan 09

Fennec Pharmaceuticals Inc : Piper Sandler Initiates Coverage With Overweight Rating; Target Price $18

THOMSON REUTERS
·
Jan 09

Fennec initiated with an Overweight at Piper Sandler

TIPRANKS
·
Jan 09

Southpoint Capital Advisors Reports Sale of Fennec Pharmaceuticals Common Shares

Reuters
·
Dec 30, 2025

Southpoint Capital Advisors- Southpoint Controls 2.7 Mln Common Shares, 8% of Outstanding Common Shares of Fennec

THOMSON REUTERS
·
Dec 27, 2025

Southpoint holdings in Fennec Pharmaceuticals Inc. (TSX: FENC)

GlobeNewswire
·
Dec 27, 2025

Fennec Pharmaceuticals Inc - Study to Evaluate Pedmark for Preventing Cisplatin-Induced Ototoxicity

THOMSON REUTERS
·
Dec 09, 2025

Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors

GlobeNewswire
·
Dec 09, 2025

Director Rosty Raykov Reports Sale of Fennec Pharmaceuticals Inc. Common Shares

Reuters
·
Dec 06, 2025

BRIEF-Fennec Pharmaceuticals Announces Positive Topline Results

Reuters
·
Dec 02, 2025

Fennec Pharmaceuticals Reports Positive Results for PEDMARK in Japanese Pediatric Cancer Study

Reuters
·
Dec 02, 2025

Fennec Pharmaceuticals Inc - Plans to Pursue Registration for Pedmark in Japan

THOMSON REUTERS
·
Dec 02, 2025

Fennec Pharmaceuticals Inc - Pedmark Showed No Interference With Cisplatin Antitumor Activity

THOMSON REUTERS
·
Dec 02, 2025

Fennec Pharmaceuticals Inc - Study Shows Significant Reduction in Hearing Loss in 3-18 Year Olds

THOMSON REUTERS
·
Dec 02, 2025

Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss

GlobeNewswire
·
Dec 02, 2025

Fennec Pharmaceuticals Unveils Presentation Highlighting PEDMARK’s Role in Preventing Hearing Loss from Cancer Treatment

Reuters
·
Dec 01, 2025

Southpoint Capital Advisors LP Reports Disposal of Fennec Pharmaceuticals Inc. Common Shares

Reuters
·
Nov 21, 2025

Analysts Are Bullish on These Healthcare Stocks: Fennec Pharmaceuticals (FENC), Boston Scientific (BSX)

TIPRANKS
·
Nov 19, 2025

Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption

GlobeNewswire
·
Nov 19, 2025